Quiver Bioscience
- Biotech or pharma, therapeutic R&D
Quiver Bioscience is a neuroscience-focused therapeutics company progressing their first two assets, one a non-opioid Nav1.7 genetic medicine, and the second targeting UBE3A in a severe neurodevelopmental disease, into the clinic next year. The company's unique strength comes from its platform, which uses patient-derived models and translates the signals from these neurons into machine-readable optical signals, creating a new data layer for drug discovery. The foundational platform, originally licensed from Harvard, has been perfected and further augmented by the Quiver team over the past 10+ years, representing a new scalable approach that overcomes many of the historical challenges with drug discovery for brain-related indications. The platform has already yielded an asset that is currently through phase I for ALS (collaboration with QurAlis) and has been the basis of Quiver's 10+ pharma partnerships (notably including with Vertex, UCB, Angelini, Biohaven, and QurAlis).
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}